According to the 27 July announcement, Prendergast next week in Florida will be presenting “expanded details of in-vitro, in-vivo and human clinical trial data” on R327’s relevance to the treatment of wound infections in military personnel. “A non-confidential version of the Poster and Abstract materials will be available on the Company’s website, post-conference.”
The details in this Special Access announcement make it pretty clear what value R327 could hold for the health and functioning of the US military. It would not be a customer needing to wait for commercial regulatory approvals, and also would have ready access to trial ‘volunteers’ if required (and research funds?).
RCE Price at posting:
70.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)